Weekly Recap

Cenobamate Gets New Approved Administration Routes, FDA Agrees to New Trial Design for NurOwn, ENRICH Results Published in NEJM

ByNeurologyLive® Staff

April 13th 2024

Neurology News Network. for the week ending April 13, 2024. [WATCH TIME: 3 minutes]

Amylyx Pulls ALS Drug AMX0035, Gene Therapy Shows Promise in Giant Axonal Neuropathy, Eisai Submits sBLA for New Lecanemab Dosing

ByNeurologyLive® Staff

April 6th 2024

Neurology News Network. for the week ending April 6, 2024. [WATCH TIME: 3 minutes]

NeuroVoices: Francesco Saccà, MD, PhD, on Crossing Over Dimethyl Fumarate in Friedriech Ataxia

ByMarco Meglio

April 3rd 2024

The associate professor of neurology at the University of Naples discussed a recently enrolled study assessing the use of dimethyl fumarate, an approved therapy for relapsing MS and psoriasis, in patients with Friedreich ataxia.

STK-001 Shows Disease-Modifying Impacts in Dravet, FDA Approves Ravulizumab, Satralizumab Falls Short in Myasthenia Gravis

ByNeurologyLive® Staff

March 30th 2024

Neurology News Network. for the week ending March 30, 2024. [WATCH TIME: 3 minutes]

SLS-005 Performs Better Without AMX0035, Nerivio Gains Commercial Coverage, UB-312 Reduces α-Synuclein

ByNeurologyLive® Staff

March 23rd 2024

Neurology News Network for the week ending March 23, 2024. [WATCH TIME: 3 minutes]

Positive Phase 1 Study of Monepantel, CRL Given to GA Depot, FDA Rejects Tasimelteon sNDA

ByNeurologyLive® Staff

March 16th 2024

Neurology News Network for the week ending March 16, 2024. [WATCH TIME: 3 minutes]

EPIDYS Trial Supports Givinostat's Efficay, SRP-9001 in EMBARK Study, Eteplirsen Shows Long-Term Safety

ByNeurologyLive® Staff

March 9th 2024

Neurology News Network for the week ending March 9, 2024. [WATCH TIME: 3 minutes]

ATH-1105 Shows Promise as ALS Treatment, Eplontersen Granted Fast Track for ATTR Cardiomyopathy, Poor Oral Health Linked to Brain Profiles

ByNeurologyLive® Staff

March 2nd 2024

Neurology News Network for the week ending March 1, 2024. [WATCH TIME: 3 minutes]

CGRP and Gepant Combination Safe, DNL788 Fails ALS Study, Frexalimab Promising Phase 2 Results in Relapsing MS

ByNeurologyLive® Staff

February 24th 2024

Neurology News Network for the week ending February 24, 2024. [WATCH TIME: 3 minutes]

Laquinimod Reduces Caudate Volume in Huntington, Assisted Reproductive Technologies Increase In-Hospital Stroke Risk, Omaveloxolone Approved in EU

ByNeurologyLive® Staff

February 17th 2024

Neurology News Network for the week ending February 17, 2024. [WATCH TIME: 3 minutes]

Adrenomedullin Safe in Ischemic Stroke, NfL and GFAP Levels Identified During Stroke, Fibrinogenase Improves Functional Outcomes

ByNeurologyLive® Staff

February 10th 2024

Neurology News Network for the week ending February 10, 2024. [WATCH TIME: 3 minutes]

Biogen Discontinues Aducanumab, CHMP Issues Negative Opinion on Ataluren, SRP-5051 Shines in MOMENTUM Study

ByNeurologyLive® Staff

February 3rd 2024

Neurology News Network for the week ending February 3, 2024. [WATCH TIME: 3 minutes]

Cell Therapy HLCM051 Falls Short in Stroke Study, Benefits of Light Therapy in Alzheimer, IPL344 Phase 2a Data Released

ByNeurologyLive® Staff

January 27th 2024

Neurology News Network for the week ending January 27, 2024. [WATCH TIME: 3 minutes]

ALS Agent PrimeC Moves to Phase 3, FDA Clears IND for AB126, APOE Carrier Status Impacts ARIA

ByNeurologyLive® Staff

January 20th 2024

Neurology News Network for the week ending January 21, 2024. [WATCH TIME: 3 minutes]

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

ByMarco Meglio

January 13th 2024

Neurology News Network for the week ending January 13, 2024. [WATCH TIME: 4 minutes]

ALS Agent CNM-Au8 Reduces NfL, Positive CLEAR-MIND Results, Decreased Learning Abilities in Narcolepsy

ByNeurologyLive® Staff

January 6th 2024

Neurology News Network for the week ending January 6, 2023. [WATCH TIME: 3 minutes]

Trial of Ptau Therapy ACI-35.030 Launched, Positive Data on AMT-130 in Huntington Disease, CHMP Recommends EU Approval of Omeveloxolone

ByNeurologyLive® Staff

December 23rd 2023

Neurology News Network for the week ending December 23, 2023. [WATCH TIME: 4 minutes]

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

ByNeurologyLive® Staff

December 16th 2023

Neurology News Network for the week ending December 16, 2023. [WATCH TIME: 3 minutes]

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

ByNeurologyLive® Staff

December 9th 2023

Neurology News Network for the week ending December 9, 2023. [WATCH TIME: 3 minutes]

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

ByNeurologyLive® Staff

December 2nd 2023

Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

ByNeurologyLive® Staff

November 25th 2023

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

ByNeurologyLive® Staff

November 18th 2023

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

ByNeurologyLive® Staff

November 11th 2023

Neurology News Network for the week ending November 11, 2023. [WATCH TIME: 3 minutes]

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

ByNeurologyLive® Staff

November 4th 2023

Neurology News Network for the week ending November 4, 2023. [WATCH TIME: 3 minutes]

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

ByNeurologyLive® Staff

October 21st 2023

Neurology News Network for the week ending October 21, 2023. [WATCH TIME: 3 minutes]

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

ByNeurologyLive® Staff

October 14th 2023

Neurology News Network for the week ending October 14, 2023. [WATCH TIME: 3 minutes]

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

ByNeurologyLive® Staff

October 7th 2023

Neurology News Network for the week ending October 7, 2023. [WATCH TIME: 3 minutes]

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

ByNeurologyLive® Staff

September 30th 2023

Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

ByNeurologyLive® Staff

September 23rd 2023

Neurology News Network for the week ending September 23, 2023. [WATCH TIME: 3 minutes]

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

ByNeurologyLive® Staff

September 16th 2023

Neurology News Network for the week ending September 16, 2023. [WATCH TIME: 3 minutes]

Weekly Recap

Cenobamate Gets New Approved Administration Routes, FDA Agrees to New Trial Design for NurOwn, ENRICH Results Published in NEJM

Amylyx Pulls ALS Drug AMX0035, Gene Therapy Shows Promise in Giant Axonal Neuropathy, Eisai Submits sBLA for New Lecanemab Dosing

NeuroVoices: Francesco Saccà, MD, PhD, on Crossing Over Dimethyl Fumarate in Friedriech Ataxia

STK-001 Shows Disease-Modifying Impacts in Dravet, FDA Approves Ravulizumab, Satralizumab Falls Short in Myasthenia Gravis

SLS-005 Performs Better Without AMX0035, Nerivio Gains Commercial Coverage, UB-312 Reduces α-Synuclein

Positive Phase 1 Study of Monepantel, CRL Given to GA Depot, FDA Rejects Tasimelteon sNDA

EPIDYS Trial Supports Givinostat's Efficay, SRP-9001 in EMBARK Study, Eteplirsen Shows Long-Term Safety

ATH-1105 Shows Promise as ALS Treatment, Eplontersen Granted Fast Track for ATTR Cardiomyopathy, Poor Oral Health Linked to Brain Profiles

CGRP and Gepant Combination Safe, DNL788 Fails ALS Study, Frexalimab Promising Phase 2 Results in Relapsing MS

Laquinimod Reduces Caudate Volume in Huntington, Assisted Reproductive Technologies Increase In-Hospital Stroke Risk, Omaveloxolone Approved in EU

Adrenomedullin Safe in Ischemic Stroke, NfL and GFAP Levels Identified During Stroke, Fibrinogenase Improves Functional Outcomes

Biogen Discontinues Aducanumab, CHMP Issues Negative Opinion on Ataluren, SRP-5051 Shines in MOMENTUM Study

Cell Therapy HLCM051 Falls Short in Stroke Study, Benefits of Light Therapy in Alzheimer, IPL344 Phase 2a Data Released

ALS Agent PrimeC Moves to Phase 3, FDA Clears IND for AB126, APOE Carrier Status Impacts ARIA

CBD Leads to Nonseizure Improvements, AbbVie Launches 24-Hour Levodopa Infusion in EU, CNM-Au8 Improves Visual Function and Cognition

ALS Agent CNM-Au8 Reduces NfL, Positive CLEAR-MIND Results, Decreased Learning Abilities in Narcolepsy

Trial of Ptau Therapy ACI-35.030 Launched, Positive Data on AMT-130 in Huntington Disease, CHMP Recommends EU Approval of Omeveloxolone

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA

Zola-Cel and Treatment-Free Remission: What the BREAKFREE-2 Data Show

Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis

Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials

Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy